Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New study offers hope for ASF vaccine
ASF currently has no vaccine but the disease is spreading further across Europe. (stock photo)
Deleting a gene reduces ability to cause infection 

Genetically altering the African swine fever virus could offer the key to a much-needed vaccine for the deadly disease, Pirbright scientists say.

Researchers found that by deleting a gene of the virus, it was still able to replicate, but its ability to cause infection was dramatically reduced. The gene they deleted codes for a protein thought to play a role in suppressing the pig immune system.

All pigs involved in the study survived, and displayed only mild clinical signs. Furthermore, they were protected against further infection from a natural strain of ASFV, which causes severe disease.

ASF currently has no vaccine but the disease is spreading further across Europe, with outbreaks recently reported in Romania for the first time. Current prevention strategies are focused on import controls and educating farm owners, but the Pirbright Institute says these tools are not robust enough to stop the spread of disease across Eastern Europe and Russia.

The research team believe that further research could lead to an ASF vaccine. Their research shows the modified virus could be used as a component of a live attenuated vaccine, which contains a weakened version of the virus that is able to cause an immune response, without causing the animal harm.

However, issues with safety and effectiveness must be resolved before it is available commercially. The next step will be to make more gene deletions to reduce the clinical signs displayed by pigs after vaccination.

Dr Nixon added: “We will also be investigating the precise role the protein plays during infection. This information will help us understand how it interacts with the host immune system and if the protein directly prevents immune processes or if it has other roles we haven’t yet identified.

“Knowing more about the gene and protein will make it easier for us to modify the virus further and create a vaccine that is effective and safe.”

The findings have been published in the Journal of Virology.

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
New guidance for antibiotic use in rabbits

New best practice guidance on the responsible use of antibiotics in rabbits has been published by the BSAVA in collaboration with the Rabbit Welfare Association & Fund (RWA&F).

The guidance is free and has been produced to help veterinary practitioners select the most appropriate antibiotic for rabbits. It covers active substance, dose and route of administration all of which are crucial factors when treating rabbits owing to the risk of enterotoxaemia.

For more information and to access the guide, visit the BSAVALibrary.